Structure-based virtual screening for identification of novel 11β-HSD1 inhibitors

European Journal of Medicinal Chemistry

Volumn 44, Issue 3, 2009, Pages 1167-1171

  Yang, Huaiyu ^a   Shen, Yu ^a   Chen, Junhua ^a   Jiang, Qunfeng ^a   Leng, Ying ^a   Shen, Jianhua ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

11 HSD1; 11 HSD2; Docking; Inhibitor; Pharmacophore

Indexed keywords

11 BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR DERIVATIVE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; ARYLSULFONAMIDO; BVT 3498; INCB 13739; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG SCREENING; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; PHARMACOPHORE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; ENZYME INHIBITORS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 60849135109     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.06.005     Document Type: Article

References (20)

1. Arnaldi G., Angeli A., Atkinson A.B., Bertagna X., Cavagnini F., Chrousos G.P., Fava G.A., Findling J.W., Gaillard R.C., Grossman A.B., Kola B., Lacroix A., Mancini T., Mantero F., Newell-Price J., Nieman L.K., Sonino N., Vance M.L., Giustina A., and Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88 (2003) 5593-5602
2. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., and Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 109 (2004) 433-438
3. Inagaki K., Otsuka F., Miyoshi T., Watanabe N., Suzuki J., Ogura T., and Makino H. Reversible pituitary dysfunction in a patient with Cushing's syndrome discovered as adrenal incidentaloma. Endocr. J. 51 (2004) 201-206
4. Kotelevitsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C.R.W., Seckl J.R., and Mullins J.J. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 14924-14929
5. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., and Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
6. Kershaw E.E., Morton N.M., Dhillon H., Ramage L., Seckl J.R., and Flier1 J.S. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54 (2005) 1023-1031
7. Barf T., and Williams M. Recent progress in 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) inhibitor development. Drugs Future 31 (2006) 231-243
8. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
9. Joseph-McCarthy D., and Alvarez J.C. Automated generation of MCSS-derived pharmacophoric DOCK site points for searching multiconformation databases. Proteins 51 (2003) 189-202
10. Barreca M.L., De Luca L., Iraci N., Rao A., Ferro S., Maga G., and Chimirri A. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J. Chem. Inf. Model. 47 (2007) 557-562
11. Schuster D., Maurer E.M., Laggner C., Nashev L.G., Wilckens T., Langer T., and Odermatt A. The discovery of new 11β-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J. Med. Chem. 49 (2006) 3454-3466
12. Yang H., Dou W., Lou J., Leng Y., and Shen J. Discovery of novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. Bioorg. Med. Chem. Lett. 18 (2008) 1340-1345
13. Patel J.R., Shuai Q., Dinges J., Winn M., Pliushchev M., Fung S., Monzon K., Chiou W., Wang J., Pan L., Wagaw S., Engstrom K., Kerdesky F.A., Longenecker K., Judge R., Qin W., Imade H.M., Stolarik D., Beno D.W., Brune M., Chovan L.E., Sham H.L., Jacobson P., and Link J.T. Discovery of adamantane ethers as inhibitors of 11β-HSD-1: synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 17 (2007) 750-755
14. Wolber G., and Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45 (2005) 160-169
15. Catalyst, Version 4.9 (2006), Accelrys Inc., San Diego, CA
16. Schrödinger (2005), LLC, New York, NY
17. Zheng S., Luo X., Chen G., Zhu W., Shen J., Chen K., and Jiang H. A new rapid and effective chemistry space filter in recognizing a druglike database. J. Chem. Inf. Model. 45 (2005) 856-862
18. Mundt S., Solly K., Thieringer R., and Hermanowski-Vosatka A. Development and application of a scintillation proximity assay (SPA) for identification of selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Assay Drug Dev. Technol. 3 (2005) 367-375
19. The PyMOL Molecular Graphics System, Version 0.99 (2002), DeLano Scientific, San Carlos, CA, U.S.A.
20. Barf T., Vallgårda J., Emond R., Häggström C., Kurz G., Nygren A., Larwood V., Mosialou E., Axelsson K., Olsson R., Engblom L., Edling N., Rönquist-Nii Y., Öhman B., Alberts P., and Abrahmsén L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 45 (2002) 3813-3815